Tech Company Financing Transactions
Bellicum Pharmaceuticals Funding Round
On 3/12/2012, Bellicum Pharmaceuticals announced $20 million in Series B investment from Remeditex Ventures and private investors.
Transaction Overview
Company Name
Announced On
3/12/2012
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Investors
Remeditex Ventures (Dennis Stone)
Proceeds Purpose
The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2130 West Holcombe Blvd. 800
Houston, TX 77030
USA
Houston, TX 77030
USA
Phone
Website
Email Address
Overview
Bellicum is a clinical stage company focused on developing novel cellular immunotherapies for certain cancers and orphan inherited blood disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rick Fair
VP - Bus. Development
Gregory Naeve
VP - Finance
Rosie Williams
VP - Manufacturing
Joseph Senesac
VP - Operations
Alan Smith
VP - Product Management
Aaron Foster
Browse more venture capital transactions:
Prev: 3/12/2012: HemaQuest Pharmaceuticals venture capital transaction
Next: 3/13/2012: Apperian venture capital transaction
Share this article
News on VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs